Salvin Dental Specialties, a Young Innovations company, has introduced OraGen, the first viable dental bone allograft that combines cryopreserved corticocancellous bone with a demineralized bone matrix. This cutting-edge formulation provides three critical properties for bone regeneration—osteogenicity, osteoconductivity, and osteoinduction—delivering optimal support for complex dental procedures.
Unlike traditional bone grafts, OraGen contains lineage-committed bone cells that actively generate new bone (osteogenicity), ensuring a dynamic healing environment. Its biocompatible scaffold promotes cell attachment and growth (osteoconductivity), while retained natural growth factors stimulate bone repair and regeneration (osteoinduction). This powerful combination makes OraGen an ideal choice for sinus and ridge augmentation as well as the repair of large defects in the mandible and maxilla.
Designed to support predictable clinical outcomes, OraGen is an innovative solution for implant site development and complex reconstructive cases. The cryopreservation process maintains cellular viability, further enhancing bone integration and healing potential. By offering a viable, all-in-one bone grafting solution, Salvin Dental continues its commitment to providing advanced regenerative solutions for dental professionals.
To learn more about OraGen and how it can enhance bone regeneration success, visit www.salvin.com or call 800-535-6566.